Literature DB >> 24046168

[Neuroprotective approaches].

S Thaler1, C Haritoglou, F Schuettauf.   

Abstract

After introduction of vitreoretinal surgery more than 40 years ago, further development of the procedure involved a continuous reduction of potential toxic effects by irrigating solutions, endoillumination or mechanical manipulation. Recently, additional efforts were made to prevent neurodegeneration via pharmacological intervention. Taurine as additive for irrigating solutions can be considered as an example for neuroprotectants in vitreoretinal surgery. Approval of neuroprotective agents demands an increased effort for preclinical and clinical evaluation. To date, only few neuroprotective substances are used in clinical routine in the context of vitreoretinal surgery, however, experimental data suggest a high potential of various neuroprotective agents. The following article gives an overview of current neuroprotective approaches feasible for vitreoretinal surgery and a critical analysis of their clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24046168     DOI: 10.1007/s00347-013-2831-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  29 in total

1.  Neuroprotective effects of a taurine-containing irrigation solution for vitrectomy.

Authors:  Maximilian Schultheiss; Hannah Ruschenburg; Max Warga; Charlotte Schramm; Kai Januschowski; Sven Schnichels; Tilo Biedermann; Peter Szurman; Martin S Spitzer
Journal:  Retina       Date:  2012-07       Impact factor: 4.256

2.  Testing the biocompatibility of a glutathione-containing intra-ocular irrigation solution by using an isolated perfused bovine retina organ culture model - an alternative to animal testing.

Authors:  Kai Januschowski; Ahmad Zhour; Albert Lee; Ramin Maddani; Sebastien Mueller; Martin S Spitzer; Sven Schnichels; Maximilian Schultheiss; Deshka Doycheva; Karl-Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Altern Lab Anim       Date:  2012-03       Impact factor: 1.303

3.  Vitrectomy: a pars plana approach.

Authors:  R Machemer; H Buettner; E W Norton; J M Parel
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1971 Jul-Aug

4.  Neuroprotective effects of tempol acyl esters against retinal ganglion cell death in a rat partial optic nerve crush model.

Authors:  Sebastian Thaler; Michal Fiedorowicz; Pawel Grieb; Zbigniew Wypych; Narcyz Knap; Tomasz Borowik; Katarzyna Zawada; Jaroslaw Kaminski; Michal Wozniak; Robert Rejdak; Eberhart Zrenner; Frank Schuettauf
Journal:  Acta Ophthalmol       Date:  2011-06-03       Impact factor: 3.761

5.  Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity.

Authors:  Frank Schuettauf; Christian Vorwerk; Rita Naskar; Anton Orlin; Kristine Quinto; David Zurakowski; Nadine S Dejneka; Ronald L Klein; Edward M Meyer; Jean Bennett
Journal:  Curr Eye Res       Date:  2004-12       Impact factor: 2.424

6.  Tempol protects against intravitreous indocyanine green-induced retinal damage in rats.

Authors:  Sebastian Thaler; Bogomil Voykov; Gabriel Willmann; Michal Fiedorowicz; Robert Rejdak; Florian Gekeler; C Albrecht May; Andreas Schatz; Frank Schuettauf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-31       Impact factor: 3.117

7.  Memantine for axonal loss of optic neuritis.

Authors:  Mohammad Riazi Esfahani; Zahra Alami Harandi; Morteza Movasat; Mojgan Nikdel; Mohsen Adelpour; Arezo Momeni; Hamid Merat; Masoud Aghsaei Fard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-16       Impact factor: 3.117

8.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress.

Authors:  Pranab K Mukherjee; Victor L Marcheselli; Charles N Serhan; Nicolas G Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-19       Impact factor: 11.205

10.  An in vivo evaluation of Brilliant Blue G in animals and humans.

Authors:  M Remy; S Thaler; R G Schumann; C A May; M Fiedorowicz; F Schuettauf; M Grüterich; S G Priglinger; M M Nentwich; A Kampik; C Haritoglou
Journal:  Br J Ophthalmol       Date:  2008-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.